<DOC>
	<DOC>NCT02556138</DOC>
	<brief_summary>The purpose of this study is to determine whether the ORBERA Intragastric Balloon is a safe and effective means for weight loss and improved metabolic disease in patients with cirrhosis requiring liver transplantation.</brief_summary>
	<brief_title>Endoscopic Intragastric Balloon Placement for Weight Loss in Liver Transplant Waitlist Candidates</brief_title>
	<detailed_description />
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Adults (&gt;18 years) with endstage liver disease who are listed for liver transplant Have failed the noninvasive approach to weight loss to be actively listed for transplant (requiring 2 clinical return visits without weight loss of &gt;5 kg) Body Mass Index (BMI) &gt;35 Age &gt;18 years Negative pregnancy test for females who are able to get pregnant and are of childbearing age A previous history of gastric or bariatric surgery Current or recent (within 6 months) gastric or duodenal ulcers Moderate to severe Portal hypertension defined as portal gastropathy graded as &gt;= to moderate/severe, gastric varices, or esophageal varices graded &gt; = moderate/large (Patients with varices which have been obliterated may be included). Calculated MELD score &gt;25 or childs score &gt;10 The presence of more than one gastric balloon at the same time Any inflammatory disease of the gastrointestinal tract including esophagitis, gastric ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn's disease. A large hiatal hernia or &gt;5 cm hernia or â‰¤5 cm with associated severe or intractable gastroesophageal reflux symptoms. A structural abnormality in the esophagus or pharynx such as a stricture or diverticulum that could impede passage of the delivery catheter and/or an endoscope. Achalasia or any other severe motility disorder that may pose a safety risk during removal of the device. Gastric mass Severe coagulopathy Patients who are known to have or suspected to have an allergic reaction to materials contained in ORBERA. Serious or uncontrolled psychiatric illness or disorder that could compromise patient understanding of or compliance with follow up visits and removal of the device after 6 months. Alcoholism or drug addiction Patients who are unable or unwilling to take prescribed proton pump inhibitor medication for the duration of the device implant Patients unwilling to participate in an established medicallysupervised diet and behavior modification program, with routine medical followup. Patients receiving aspirin, antiinflammatory agents, anticoagulants or other gastric irritants, not under medical supervision.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Intragastric Balloon</keyword>
	<keyword>ORBERA Intragastric Balloon</keyword>
	<keyword>Weight Loss</keyword>
	<keyword>BMI &gt;35</keyword>
</DOC>